Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
74 hedge funds and large institutions have $46.7M invested in Navidea Biopharmaceuticals Inc. in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 78 → 74 (-4)
15% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 20
22% less capital invested
Capital invested by funds: $60.2M → $46.7M (-$13.4M)
24% less call options, than puts
Call options by funds: $65K | Put options by funds: $85K
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Platinum Management
New York
|
+$11.7M |
| 2 |
D.E. Shaw & Co
New York
|
+$95.1K |
| 3 |
SG Americas Securities
New York
|
+$93.5K |
| 4 |
Citigroup
New York
|
+$79K |
| 5 |
RFC
Russell Frank Company
Seattle,
Washington
|
+$67.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.87M |
| 2 |
Renaissance Technologies
New York
|
-$807K |
| 3 |
Goldman Sachs
New York
|
-$277K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$200K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$160K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
76
Virtu KCG Holdings
New York
| – | -$138K | -5,204 | Closed |
|
77
Millennium Management
New York
| – | -$106K | -3,968 | Closed |
|
|
ARTA
78
A.R.T. Advisors
New York
| – | -$62K | -2,359 | Closed |
|
79
BNP Paribas Financial Markets
Paris,
France
| – | -$38.7K | -1,455 | Closed |
|
|
RCM
80
Rotella Capital Management
Bellevue,
Washington
| – | -$30K | -1,120 | Closed |
|
|
TRCT
81
Tower Research Capital (TRC)
New York
| – | -$23K | -874 | Closed |
|
|
TSS
82
Two Sigma Securities
New York
| – | -$20K | -752 | Closed |
|
|
GC
83
Guggenheim Capital
Chicago,
Illinois
| – | -$20K | -745 | Closed |
|
84
Barclays
London,
United Kingdom
| – | -$12.5K | -647 | -87% |
|
|
IA
85
IFP Advisors
Tampa,
Florida
| – | -$3K | -100 | Closed |
|
86
Simplex Trading
Chicago,
Illinois
| – | -$770 | -40 | Closed |
|
NAVB Hedge Fund Activity: Q1 2016 in Review
74 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2016, worth a combined $46.7M — down 22% from $60.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NAVB and 8 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 17 added.
The largest buyer was Platinum Management, adding an estimated $11.7M. The largest seller was Susquehanna International Group, cutting an estimated $5.87M.
- 74 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2016, down from 78 in Q4 2015.
- Funds reported $46.7M of Navidea Biopharmaceuticals Inc. stock for Q1 2016, down 22% quarter-over-quarter.
- 8 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2016 and 12 closed out, a net change of -4 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2016 was Platinum Management, an estimated $11.7M added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q1 2016 was Susquehanna International Group, an estimated $5.87M sold.
Based on aggregated 13F filings for Q1 2016.